^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRMT1 inhibitor

    i
    Other names: PRMT1 inhibitor
    Associations

    News

    Trials
    Company:
    Bionomics, Cancer Therapeutics CRC
    Drug class:
    PRMT1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. (PubMed, Nat Commun)
    Taken together, our data support PRMT1 as a compelling target in PDAC and informs a mechanism-based translational strategy for future therapeutic development.Statement of significancePDAC is a highly lethal cancer with limited therapeutic options. This study identified and characterized PRMT1-dependent regulation of RNA metabolism and coordination of key cellular processes required for PDAC tumor growth, defining a mechanism-based translational hypothesis for PRMT1 inhibitors.
    Journal
    |
    PRMT1 (Protein Arginine Methyltransferase 1)
    |
    PRMT1 inhibitor